ENGN

enGene Therapeutics Inc. (ENGN) | Rumor.io

enGene Therapeutics

ENGN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,488

Bullish sentiment (50-day avg)88%

Price to earnings ratio-0.86

Market capitalization132M

Earnings per share-2.07

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-117.3M

Social

What share of all stock conversation is about ENGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% +0

May 15

enGene Holdings Inc. ($ENGN) has seen a significant drop in shares held by Cormorant Asset Manager, a former major shareholder.
The stock's current price is considered undervalued, with some analysts believing it is worth at least $4 per share.
There are potential catalysts for the stock's price to increase, including upcoming FDA talks and BLA submission plans, which could lead to approvals and a subsequent rise in price.

Generated by AI

Sentiment

Of the messages about ENGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	66.67% -24.64	74.65% -4.74
Bearish	—	0%	33.33% +24.64	25.35% +4.74

Bullish· May 14

A large institutional investor, BML Investment Partners, has accumulated a significant stake in enGene Holdings Inc., owning 10% of the company's shares.
The accumulation of shares by BML Investment Partners has sparked optimism among investors, with some predicting a potential increase in the stock price to at least $4.
The company's recent performance, including a 17.21% increase in stock price, has been attributed to the upcoming FDA event and the potential for positive data from the blader rinse protocol.

Bearish· May 8

The company has a $100M self-offering faucet that is absorbing buy orders, potentially leading to a lower stock price.
The CEO may be diluting shares and raising cash for personal gain, which could be a negative sign for investors.
The company has a large cash reserve of $300M, but this may not be enough to justify its current stock price, potentially leading to a downward trend.

Generated by AI

Topics

Of the messages about ENGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	56.76%
Analysts	—	0%	0%	7.9%
Controversies	—	0%	0%	0.13%
Earnings	—	0%	0%	0.4%
Macro	—	0%	0%	23.83%
Technical Analysis	—	0%	0%	10.98%

Announcements· Nov 11

enGene Holdings Inc. (ENGN) reports improved complete response rates for its bladder cancer therapy, detalimogene voraplasmid, with a 62% complete response rate at six months in the Phase 2 LEGEND trial.
The treatment demonstrated a favorable safety profile, with 42% of patients reporting treatment-related adverse events, and only 1.6% experiencing dose interruptions.
The company updated the primary endpoint of the pivotal cohort to the overall complete response rate, with duration of response designated as a key secondary endpoint, following discussions with the FDA.

Technical Analysis· Nov 11

$ENGN is showing signs of a potential breakout, with a strong close above $9.50 potentially opening up $11.00 as a next target.
The stock has a bullish flag formation on the minutely to daily charts, with potential targets indicated, despite intense short-selling.
$ENGN is currently in a downtrend, but has shown a short-term bounce, with RSI 17.8 being deeply oversold and MACD starting to curl up, indicating potential for a squeeze.

Generated by AI

Community

Of the messages about ENGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	25%	45.45%	6.42%
Newcomers	—	75%	54.55%	93.58%

May 8

Newcomers are focusing on the company's durability print, which came in softer than expected, leading to a significant stock drop.
Some newcomers are optimistic about the company's potential for approval, despite the recent underwhelming results, and believe the stock will correct to the upside in the coming days.
The company's cash and debt situation is being discussed, with some pointing out that the company has a significant amount of cash and securities, and others are concerned about the potential for a raid or takeover.

Generated by AI

News

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Definium Therapeutics (DFTX) and enGene Holdings (ENGN)

Detailed price information for Engene Therapeutics Inc (ENGN-Q) from The Globe and Mail including charting and trades.

12d agoThe Globe and Mail

enGene at Morgan Stanley conference: bladder cancer push gains momentum

15d agoInvesting.com

enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market

19d agoSeeking Alpha

Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Detailed price information for Engene Therapeutics Inc (ENGN-Q) from The Globe and Mail including charting and trades.

20d agoThe Globe and Mail

Engene Holdings stock rating maintained at Market Perform by Citizens

21d agoInvesting.com

enGene at Wells Fargo conference: bladder cancer push gains focus

21d agoInvesting.com

Also Discussed

Investors talking about ENGN also mention

#	Name	Attention
1	Neuphoria Therapeutics Inc.NEUP	0%0
2	Motorsport Games Inc. Class A Common StockMSGM	0%0
3	SGN - Signing Day Sports, Inc.	——
4	Turbo Energy, S.A. American Depositary SharesTURB	0.01%new
5	SNCE - Science 37 Holdings, Inc.	——
6	Direxion Daily AMD Bear 1X ETFAMDD	0%new
7	F/m Ultrashort Treasury Inflation-Protected Security (TIPS) ETFRBIL	0%0
8	MultiSensor AI Holdings Inc.MSAI	0%0
9	Telomir Pharmaceuticals, Inc.TELO	0%0
10	Apollomics Inc.APLM	0%0

enGene Therapeutics Inc.

Healthcare
Biotechnology

enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for diseases with significant unmet medical needs. The company’s work centers on its proprietary DDX delivery platform, which is designed to deliver DNA and RNA-based therapies directly to mucosal tissues and other target organs. Its lead product candidate, detalimogene voraplasmid, is being developed as a monotherapy for non-muscle invasive bladder cancer, including difficult-to-treat high-risk cases. enGene Therapeutics Inc. also advances a broader pipeline of gene therapy programs aimed at localized treatment delivery in oncology and other therapeutic areas. Based in Montreal, Canada, the company plays a specialized role in the biotechnology market by pursuing tissue-targeted genetic therapies that seek to address complex diseases through precision delivery approaches.

Website

Location

4868 Rue Levy

Montreal, QC, H4R 2P1

Canada

Social

What share of all stock conversation is about ENGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% +0

May 15

enGene Holdings Inc. ($ENGN) has seen a significant drop in shares held by Cormorant Asset Manager, a former major shareholder.
The stock's current price is considered undervalued, with some analysts believing it is worth at least $4 per share.
There are potential catalysts for the stock's price to increase, including upcoming FDA talks and BLA submission plans, which could lead to approvals and a subsequent rise in price.

Generated by AI

Sentiment

Of the messages about ENGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	66.67% -24.64	74.65% -4.74
Bearish	—	0%	33.33% +24.64	25.35% +4.74

Bullish· May 14

A large institutional investor, BML Investment Partners, has accumulated a significant stake in enGene Holdings Inc., owning 10% of the company's shares.
The accumulation of shares by BML Investment Partners has sparked optimism among investors, with some predicting a potential increase in the stock price to at least $4.
The company's recent performance, including a 17.21% increase in stock price, has been attributed to the upcoming FDA event and the potential for positive data from the blader rinse protocol.

Bearish· May 8

The company has a $100M self-offering faucet that is absorbing buy orders, potentially leading to a lower stock price.
The CEO may be diluting shares and raising cash for personal gain, which could be a negative sign for investors.
The company has a large cash reserve of $300M, but this may not be enough to justify its current stock price, potentially leading to a downward trend.

Generated by AI

Topics

Of the messages about ENGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	56.76%
Analysts	—	0%	0%	7.9%
Controversies	—	0%	0%	0.13%
Earnings	—	0%	0%	0.4%
Macro	—	0%	0%	23.83%
Technical Analysis	—	0%	0%	10.98%

Announcements· Nov 11

enGene Holdings Inc. (ENGN) reports improved complete response rates for its bladder cancer therapy, detalimogene voraplasmid, with a 62% complete response rate at six months in the Phase 2 LEGEND trial.
The treatment demonstrated a favorable safety profile, with 42% of patients reporting treatment-related adverse events, and only 1.6% experiencing dose interruptions.
The company updated the primary endpoint of the pivotal cohort to the overall complete response rate, with duration of response designated as a key secondary endpoint, following discussions with the FDA.

Technical Analysis· Nov 11

$ENGN is showing signs of a potential breakout, with a strong close above $9.50 potentially opening up $11.00 as a next target.
The stock has a bullish flag formation on the minutely to daily charts, with potential targets indicated, despite intense short-selling.
$ENGN is currently in a downtrend, but has shown a short-term bounce, with RSI 17.8 being deeply oversold and MACD starting to curl up, indicating potential for a squeeze.

Generated by AI

Community

Of the messages about ENGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	25%	45.45%	6.42%
Newcomers	—	75%	54.55%	93.58%

May 8

Newcomers are focusing on the company's durability print, which came in softer than expected, leading to a significant stock drop.
Some newcomers are optimistic about the company's potential for approval, despite the recent underwhelming results, and believe the stock will correct to the upside in the coming days.
The company's cash and debt situation is being discussed, with some pointing out that the company has a significant amount of cash and securities, and others are concerned about the potential for a raid or takeover.

Generated by AI

enGene Therapeutics

Social

May 15

Bullish· May 14

Bearish· May 8

Announcements· Nov 11

Technical Analysis· Nov 11

May 8

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Definium Therapeutics (DFTX) and enGene Holdings (ENGN)

enGene at Morgan Stanley conference: bladder cancer push gains momentum

enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market

Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Engene Holdings stock rating maintained at Market Perform by Citizens

enGene at Wells Fargo conference: bladder cancer push gains focus

Also Discussed

enGene Therapeutics Inc.

Company Information

Location

Social

May 15

Bullish· May 14

Bearish· May 8

Announcements· Nov 11

Technical Analysis· Nov 11

May 8

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Definium Therapeutics (DFTX) and enGene Holdings (ENGN)

enGene at Morgan Stanley conference: bladder cancer push gains momentum

enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market

Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Engene Holdings stock rating maintained at Market Perform by Citizens

enGene at Wells Fargo conference: bladder cancer push gains focus

Also Discussed